This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.
Also called NCT03448419
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 312 participants
- Registry
-
NCT03448419 -
2017-004073-14
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Germany, Greece, Italy, Norway, Poland, Portugal, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03448419. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-09-30 (actual). Results posted on 2020-10-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03448419- Content hash
676013f2d9706b837923ed6d6052a0e9b6bbc354d1c6ad318fffa1c29a5496bb